Presented in partnership with BC Cancer Care The CML treatment landscape continues to evolve, with Treatment-Free Remission (TFR) becoming an increasingly important topic for patients and clinicians alike. The CML Society of Canada is proud to present this patient education and engagement event in partnership with BC Cancer Care. Together, we are committed to ensuring...Read More
Generic versions of most CML tyrosine kinase inhibitors (TKIs) are now available and widely used in Canada. This is an important development for patients and the healthcare system alike — generics can significantly reduce costs for provincial drug plans and private insurers, and in many cases improve patient access to treatment. This page explains what...Read More
English Français ⚠ Advocacy Alert Urgent: Proposed Federal Changes Could Harm CML Patients Beginning May 1, 2026, new co-payments are scheduled under the Interim Federal Health Program (IFHP), including $4 per prescription and 30% co-payments for essential medical services. For people living with CML, this is not a minor inconvenience — it is a patient...Read More
APO-IMATINIB APO-IMATINIB is indicated for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase. APO-IMATINIB is also indicated for the treatment of adult patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase or in chronic phase (after failure of interferon-alpha therapy). APO-IMATINIB is...Read More
The overarching themes for us of this years ASH is that there is a high percentage of more serious types of adverse events/side effects that are occurring with the newer TKI’s, but there is also much excitement towards increasing the number of patients who can be successfully managed off treatment as well. With regards to...Read More
Hello Everyone and welcome to our tenth annual coverage of the ASH meeting. This Year’s ASH is taking place in San Francisco California. 1st report: Minimal Residual Disease in CML – by Dr. M Mauro.Read More
ASH 2012 – Exciting as always! From the moment I stepped on to the plan my mind is preoccupied with all things related to ASH. Who will we meet there, what exciting new information will we learn. But, mostly my mind always turns back to my very first ASH in 2004 – an early Christmas...Read More
Bill C-64 was announced by the Liberal and NDP Government on February 29, 2024. To read the entire C-64 click on the link below: Bill C-64 An Act Respecting Pharmacare To See the progress of Bill C-64 The Current status is it has had a second reading in the Senate. Here is a brief critical...Read More
Done at diagnosis, it is the most precise way to diagnose CML as well as provide helpful information about your specific case of CML. An analysis of bone marrow samples confirms the presence of the Philadelphia chromosome and if other abnormalities are present. The bone marrow biopsy may be referred ot as a BMA/BMB. It...Read More
